Aiforia Technologies Plc – Managers’ Transactions

Aiforia Technologies Plc

COMPANY RELEASE, MANAGERS’ TRANSACTIONS 23 May 6:00 p.m. EEST

Aiforia Technologies Plc

COMPANY RELEASE, MANAGERS’ TRANSACTIONS 23 May 6:00 p.m. EEST

___________________________________________________________

 

Person subject to the notification requirement

Name: Jukka Tapaninen

Position: Chief Executive Officer

 

Issuer: Aiforia Technologies Oyj

LEI: 743700TJRVBX7420Y723

Notification type: INITIAL NOTIFICATION

Reference number: 15315/4/6

___________________________________________________________

 

Transaction date: 2022-05-18

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000507934

Nature of the transaction: ACQUISITION

 

Transaction details

(1): Volume: 537 Unit price: 4.1 EUR

(2): Volume: 100 Unit price: 4.1 EUR

(3): Volume: 336 Unit price: 4.037 EUR

(4): Volume: 122 Unit price: 4.1 EUR

(5): Volume: 100 Unit price: 4.7 EUR

(20): Volume: 238 Unit price: 4.049 EUR

(21): Volume: 11 Unit price: 3.9 EUR

 

Aggregated transactions

Volume: 1095 Volume weighted average price: 4.08067 EUR

___________________________________________________________

 

Transaction date: 2022-05-19

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000507934

Nature of the transaction: ACQUISITION

 

 

Transaction details

(1): Volume: 343 Unit price: 4.09850 EUR

(2): Volume: 100 Unit price: 4.09650 EUR

 

Further enquiries

 

Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc, tel. +358405009878

https://investors.aiforia.com/

 

Certified Adviser

 

UB Securities Ltd, tel. +358 9 25 380 225

 

About Aiforia

 

Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis beyond current capabilities, across a variety of fields from oncology to neuroscience and more. Find out more: www.aiforia.com